¹⁷⁷Lu-PSMA mejora la calidad de vida en pacientes con mCRPC
El viernes 17 de septiembre de 2021, Novartis anunció los hallazgos positivos más recientes del ensayo VISION: la terapia 177Lu-PSMA-617 retrasa el empeoramiento del funcionamiento físico y los síntomas de dolor en pacientes con mCRPC. Asimismo, más allá de extender la supervivencia global y de supervivencia libre de progresión, esta terapia innovadora también mejora la calidad de vida. Leer más
Die Zukunft hat begonnen. Therapie auf dem nächsten Level.
The future has started. Experience therapy on the next level.
El futuro ha comenzado. Terapia del siguiente nivel.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Therapie der Zukunft: we fight your cancer
